Solventum Co. (NYSE:SOLV – Get Free Report) has been assigned an average rating of “Hold” from the eleven brokerages that are currently covering the company, MarketBeat.com reports. One research ...

Mizuho raised the firm’s price target on Solventum (SOLV) to $82 from $70 and keeps a Neutral rating on the shares following the Q4 report. The ...

Shares of Solventum Corp. SOLV shed 4.42% to $79.75 Friday, on what proved to be an all-around positive trading session for ...

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.

Activist investor Trian Fund Management plans to push Solventum to separate more of its businesses after the company’s $4.1 ...

Solventum's $4.1B divestment to Thermo Fisher enhances financial stability, boosts EPS, and strengthens its long-term growth ...

Solventum Corp., 3M’s medtech spinoff, has sold its purification and filtration business to Massachussetts-based Thermo ...

Shares of Solventum jumped Tuesday and led S&P 500 gainers intraday after medical device maker Thermo Fisher Scientific said ...

Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...

(Reuters) -Contract drug manufacturer Thermo Fisher Scientific said on Tuesday it will buy Solventum's purification and ...

Solventum (NYSE: SOLV) today announced it has entered into a definitive agreement to sell its Purification & Filtration1 ...